Mylan's (MYL) Surprise Copaxone Generic Approval 'Quite Negative' for Teva Pharma (TEVA) - Mizuho

Teva Pharma (TEVA) PT Lowered to $15 at Morgan Stanley

Morgan Stanley lowered its price target on Teva Pharma (NYSE: TEVA) to $15.00 (from $16.00) while maintaining a Underweight rating.

Teva Pharma (TEVA) PT Lowered to $21 at Barclays; Generic Copaxone 40mg Approval 'Will Offset Some Contracting Strategies... Hurt Sentiment'

Barclays lowered its price target on Teva Pharma (NYSE: TEVA) to $21.00 (from $23.00) while maintaining a Equalweight rating, following an update on the U.S. Specialty Pharmaceutical industry, as the FDA recently approved a generic Copaxone formulation.

Analyst Douglas Tsao notes a... More

Mylan (MYL) PT Raised to $36 at Cowen; Reiterates Market Perform

Cowen raised its price target on Mylan (NASDAQ: MYL) to $36.00 (from $30.00) while maintaining a Market Perform rating. Cowen updated its model to reflect a potential $800MM in generic Copaxone contribution in 2018, and then modestly declining with other competition.

With this approval the... More

Mylan (MYL) PT Raised to $45 at BTIG Following Copaxone Generic Approval

BTIG analyst Timothy Chiang raised his price target on Mylan (NASDAQ: MYL) to $45.00 (from $42.00) while maintaining a Buy rating after the company received final FDA approval for its generic versions of Tevas (NASDAQ: TEVA) 20mg and 40mg... More

Mylan (MYL): A Big Win - BMO

BMO Capital analyst, Gary Nachman, reiterated his Outperform rating on shares of Mylan (NASDAQ: MYL) after the company received approval of glatiramer acetate 20mg and 40mg, APrated
substitutable generic versions of TEVA's Copaxone 20mg once-daily and 40mg three-times weekly injections... More

Momenta Phama (MNTA) on Watch After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone

Momenta Phama (NASDAQ: MNTA) shares were in focus after Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone. Shares declined pre-market, along with Teva Pharma (NYSE: TEVA).

Teva Pharma (TEVA) volatility flat into Mylan (MYL) granted FDA approval of Copaxone

Teva (NYSE: TEVA) October weekly call option implied volatility is at 40, October is at 41, November is at 47; compared to its 52-week range of 24 to 61 into Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone.

Mylan (MYL) volatility flat into announces FDA approval of ANDAs for Glatiramer Acetate Injection

Mylan (NASDAQ: MYL) October weekly call option implied volatility is at 30, October is at 28, November is at 34; compared to its 52-week range of 23 to 51 into announcing the FDA approval of ANDAs for Glatiramer Acetate Injection.

Teva (TEVA) Shares Pressured After Mylan (MYL) Granted FDA Approval of First Generic for Copaxone

Teva (NYSE: TEVA) shares declined after Mylan (Nasdaq: MYL) was granted FDA approval of the first generic for Copaxone. Shares declined 9% pre-market.

Mylan (MYL) Granted FDA Approval of First Generic for Copaxone

Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Food and Drug Administration (FDA) has approved Mylan's Abbreviated New Drug Applications (ANDAs) for Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection, an AP-rated, substitutable generic version of Teva's Copaxone® 40 mg/mL, and Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP-rated, substitutable generic version of Teva's Copaxone® 20 mg/mL, which are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. Mylan will begin shipping imminently.

"The FDA approvals... More